Immuron Limited
Immuron Limited
Your view on IMC.AX
Overview
What the company does, where it operates, and who runs it.
About Immuron Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Steven George Lydeamore
- Headquarters
- 62 Lygon Street, Carlton, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Steven George Lydeamore
- Headquarters
- 62 Lygon Street, Carlton, VIC, AU
Immuron Limited, an Australian biopharmaceutical firm founded in 1994 and headquartered in Carlton, is dedicated to the exploration, advancement, and worldwide commercialization of polyclonal antibodies. Operating across two divisions—Research and Development, and Hyperimmune Products—the company serves markets in Australia, Israel, Canada, the United States, and other international regions. Its current product portfolio includes Travelan, an over-the-counter remedy aimed at reducing the likelihood of travelers' diarrhea and minor gastrointestinal complaints, which also functions as a dietary supplement for digestive well-being and gut protection. Another offering, Protectyn, is an immune supplement formulated to bolster healthy digestive function and liver support. Beyond its commercialized products, Immuron is actively progressing several pipeline candidates. Travelan (IMM-124E) is currently undergoing a Phase III registration trial in the United States for the prevention of travelers' diarrhea, alongside a Phase II field trial for the same indication, and has demonstrated antiviral efficacy against SARS-CoV-2. Concurrently, IMM-529 is in Phase I/IIa clinical trials, targeting patients with recurrent Clostridium difficile infections. The company has also established key research alliances, including an agreement with the Naval Medical Research Center to develop and clinically evaluate a therapeutic agent against Campylobacter and enterotoxigenic Escherichia coli infections, and a collaborative effort with the Walter Reed Army Institute of Research to create an oral treatment for shigellosis.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Immuron Limited, and the rating behind it. IMC.AX last traded at AUD 0.03; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Immuron Limited. Starting points for Immuron Limited: EPS -AUD 0.02, beta 0.50 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Immuron Limited. Immuron Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Immuron Limited. Trailing twelve-month EPS for Immuron Limited stands at -AUD 0.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Immuron Limited. Immuron Limited has reported as a listed company since 1999. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Immuron Limited valued side by side against its closest peers. Immuron Limited is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Immuron Limited, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Immuron Limited executives and directors. Shares of Immuron Limited have traded between AUD 0.03 and AUD 0.10 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Immuron Limited. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Immuron Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Immuron Limited. Coverage tracks Immuron Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.